Answers are grounded in this paper and cite their sources.
Development of a nanovaccine (NV) that can simultaneously manipulate multiple immune cell types to activate both adaptive and innate immunity still remains a great challenge. In this study, we employed a phosphorus dendrimer (termed AK38, generation 0) with intrinsic NK cell-proliferative activity as a carrier to complex model antigen ovalbumin (OVA) and load agonist imiquimod (R837), followed by cancer cell membrane coating. The resulting AK38-OVA/R837@CM NV exhibits spherical morphology, stimuli-responsive release, excellent colloidal stability, and cytocompatibility. It promotes dendritic cell (DC) maturation and enhances antigen cross-presentation by integrating cancer cell membrane antigens, OVA, and adjuvant. Meanwhile, the NV polarizes tumor-associated macrophages (TAMs) toward the antitumor M1 phenotype, reversing immunosuppression. Importantly, the phosphorus dendrimer enables NK cell proliferation to induce tumor apoptosis. The NV synergistically activates DCs, TAMs, and NK cells, eliciting cytotoxic T lymphocyte-mediated adaptive immunity while enhancing TAM- and NK-dominated innate responses. This was validated in a murine melanoma model, where the NV effectively inhibited tumor growth and recurrence. With its simple composition and multi-cell immune cascade modulation, this phosphorus dendrimer-based NV offers a versatile tumor immunotherapy strategy, showing great promise for broad cancer treatment applications by mimicking biological systems to induce robust immune responses.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: